Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a blood pressure drug clear ICU brain fog?

NCT ID NCT04742673

First seen Feb 05, 2026 · Last updated Jun 22, 2026 · Updated 33 times

Summary

This study tested whether giving intravenous guanfacine to critically ill patients with delirium in the ICU could improve their brain function. 46 adults on breathing machines or for shock were randomly assigned to receive guanfacine or a placebo. Researchers measured days without delirium or coma, time off the ventilator, and cognitive test scores.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COGNITIVE IMPAIRMENT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37212, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Guanfacine (intravenous)

What this could lead to

If it works, this could point toward a treatment to reduce delirium and improve thinking in critically ill patients.

What could go wrong

This is a small, early-phase proof-of-concept study with only 46 participants. Results may not apply to all ICU patients, and the drug may cause side effects like low blood pressure.

Conditions

The condition(s) this trial relates to.

Cognitive Dysfunction Critical Illness delirium

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.